Gsa Capital Partners LLP Crispr Therapeutics Ag Transaction History

Gsa Capital Partners LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$43.23 - $73.83 $255,446 - $436,261	-5,909 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$53.19 - $79.24 $314,299 - $468,229	5,909 New	5,909 $371,000
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $185,528 - $294,584	-2,647 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$110.2 - $156.64 $291,699 - $414,626	2,647 New	2,647 $296,000
Q1 2020 May 12, 2020	SELL	$33.68 - $62.53 $662,350 - $1.23 Million	-19,666 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$36.68 - $73.13 $721,348 - $1.44 Million	19,666 New	19,666 $1.2 Million
Q2 2018 Aug 09, 2018	SELL	$42.62 - $73.59 $802,577 - $1.39 Million	-18,831 Closed	0 $0
Q1 2018 May 11, 2018	SELL	$23.52 - $58.17 $1.45 Million - $3.59 Million	-61,769 Reduced 76.64%	18,831 $861,000
Q4 2017 Feb 14, 2018	BUY	$16.95 - $23.48 $1.37 Million - $1.89 Million	80,600	80,600 $1.89 Million

486

58.1M

1.12M

1.73M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.65B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.